Michael A Dawes, MD
Clinical Professor, Psychiatry
Biography
Michael Dawes, M.D. is Clinical Professor in Psychiatry at Boston University School of Medicine (BUSM). Dr. Dawes is Program Director, BMC-VA Addiction Psychiatry Fellowship. Dr. Dawes has been recipient of a Mentored Clinical Scientist Development Award from the National Institute on Drug Abuse, and has been PI and Site-PI on clinical and prospective studies funded by the National Institutes of Health. He has experience designing and implementing quality improvement and systems redesign projects in the Veterans Healthcare Administration and has served as a site-PI for a multi-site study. He is currently Co-PD on a Health Resources and Services Administration (HRSA) Addiction Medicine Fellowship grant. Dr. Dawes has mentored and supervised faculty as well as many residents, fellows, and other trainees with interests in Addiction Psychiatry, Addiction Medicine, and clinical research in populations with substance use disorders. He is interested in training fellows to do clinical research, including research and implementation science addressing access to treatment for individuals and populations with substance use disorders.
Other Positions
- Program Director, Addiction Psychiatry Fellowship, Boston University Chobanian & Avedisian School of Medicine
Education
- University of North Carolina School of Medicine, MD
- University of North Carolina at Chapel Hill, BA
Publications
- Published on 10/30/2024
Sung ML, Black AC, Blevins D, Henry BF, Cates-Wessel K, Dawes MA, Hagle H, Joudrey PJ, Molfenter T, Levin FR, Fiellin DA, Edelman EJ. Clinician and Practice Characteristics Associated With Support of Office-based Methadone: Findings From a National Survey. J Addict Med. 2025 Mar-Apr 01; 19(2):150-156. PMID: 39475119.
Read at: PubMed - Published on 1/11/2022
Sung ML, Black AC, Blevins D, Henry BF, Cates-Wessel K, Dawes MA, Drexler K, Hagle H, Molfenter T, Levin FR, Becker WC, Edelman EJ. Adaptations to Opioid Use Disorder Care During the COVID-19 Pandemic: A National Survey of Prescribers. J Addict Med. 2022 Sep-Oct 01; 16(5):505-513. PMID: 35020698.
Read at: PubMed - Published on 1/1/2022
Hagedorn HJ, Wisdom JP, Gerould H, Pinsker E, Brown R, Dawes M, Dieperink E, Myrick DH, Oliva EM, Wagner TH, Harris AHS. Alcohol use disorder pharmacotherapy and treatment in primary care (ADaPT-PC) trial: Impact on identified barriers to implementation. Subst Abus. 2022; 43(1):1043-1050. PMID: 35467489.
Read at: PubMed - Published on 8/9/2021
Blevins D, Henry BF, Sung M, Edelman EJ, Black AC, Dawes M, Molfenter T, Hagle H, Drexler K, Cates-Wessel K, Levin FR. Well-Being of Health Care Professionals Treating Opioid Use Disorder During the COVID-19 Pandemic: Results From a National Survey. Psychiatr Serv. 2022 Apr 01; 73(4):374-380. PMID: 34369804.
Read at: PubMed - Published on 9/22/2020
Baig MR, Ouyang S, Mata-Galán E, Dawes MA, Roache JD. A Comparison of Cognitive Processing Therapy and Seeking Safety for the Treatment of Posttraumatic Stress Disorder in Veterans. Psychiatr Q. 2021 06; 92(2):735-750. PMID: 32964375.
Read at: PubMed - Published on 7/10/2019
Hagedorn HJ, Wisdom JP, Gerould H, Pinsker E, Brown R, Dawes M, Dieperink E, Myrick DH, Oliva EM, Wagner TH, Harris AHS. Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes. Addict Sci Clin Pract. 2019 07 10; 14(1):24. PMID: 31291996.
Read at: PubMed - Published on 9/6/2017
Harris AHS, Brown R, Dawes M, Dieperink E, Myrick DH, Gerould H, Wagner TH, Wisdom JP, Hagedorn HJ. Effects of a multifaceted implementation intervention to increase utilization of pharmacological treatments for alcohol use disorders in the US Veterans Health Administration. J Subst Abuse Treat. 2017 11; 82:107-112. PMID: 29021108.
Read at: PubMed - Published on 5/10/2016
Hagedorn HJ, Brown R, Dawes M, Dieperink E, Myrick DH, Oliva EM, Wagner TH, Wisdom JP, Harris AH. Enhancing access to alcohol use disorder pharmacotherapy and treatment in primary care settings: ADaPT-PC. Implement Sci. 2016 May 10; 11:64. PMID: 27164835.
Read at: PubMed - Published on 4/21/2016
Ling W, Hillhouse MP, Saxon AJ, Mooney LJ, Thomas CM, Ang A, Matthews AG, Hasson A, Annon J, Sparenborg S, Liu DS, McCormack J, Church S, Swafford W, Drexler K, Schuman C, Ross S, Wiest K, Korthuis PT, Lawson W, Brigham GS, Knox PC, Dawes M, Rotrosen J. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction. 2016 08; 111(8):1416-27. PMID: 26948856.
Read at: PubMed - Published on 1/26/2015
Acheson A, Ray KL, Hines CS, Li K, Dawes MA, Mathias CW, Dougherty DM, Laird AR. Functional activation and effective connectivity differences in adolescent marijuana users performing a simulated gambling task. J Addict. 2015; 2015:783106. PMID: 25692068.
Read at: PubMed
View 32 more publications: View full profile at BUMC